Drug Development

Catalent has announced the completion of a $30 million project at its facility in Limoges, France focused on biopharmaceutical development and drug product manufacturing.

NIH has launched one of the first Phase 1 clinical trials to examine mRNA technology for HIV.

C4 Therapeutics has been granted orphan drug designation by FDA for CFT8634 for the treatment of soft tissue sarcoma.

SCG Cell Therapy has signed a collaboration agreement with A*STAR’s BTI to advance the development of antibodies for infectious diseases and cancer treatments.

Novo Nordisk will expand its existing research collaboration in novel delivery technologies with MIT and Brigham and Women’s Hospital.

Evonik has launched new EUDRATEC technology to improve solubility and performance of oral small molecules.

Oculis has gained exclusive global rights to neuroprotective drug candidate for glaucoma through a licensing agreement with Accure Therapeutics.

Researchers at McGill University have made advancements with a novel method for growing synthetic bone tissue.

FDA’s CDER continues to make rare diseases a priority with drug approvals and programming to speed therapeutic development.

EMA’s PRIME scheme has enabled life-changing medicines to become available to patients at a faster rate.

Evonik has increased its global supply of plant-derived cholesterol used for mRNA vaccines and gene therapies.

TFF Pharmaceuticals and Catalent will collaborate to develop TFF's platform for manufacturing dry powder particles.

Thermo Fisher and Symphogen have extended their collaboration involving improved data workflow, which supports the discovery and development of new cancer treatments.

Technological advances are helping shape the dosage forms of the future.

Developers need to consider key challenges when approaching accelerated formulation strategies to ensure success.

Bacteriophages could be crucial weapons in the fight against antibiotic-resistant bacteria.

Adagene has announced SAFEbody multi-target collaboration with Sanofi for novel masked immuno-oncology antibody candidates.

AbbVie has acquired Syndesi Therapeutics, expanding AbbVie’s neuroscience portfolio.

Borrowing is good, but invention is best.

AstraZeneca and Neuroimmune have closed an exclusive global collaboration and license agreement to develop and commercialize NI006.

Eli Lilly and Company are investing $700 million into a Boston-based facility for the newly announced Institute for Genetic Medicine.

Alvea has begun preclinical testing of a scalable, shelf-stable DNA vaccine against SARS-CoV-2 variants.

Noema Pharma announces first patient dosed in its Phase IIb clinical trial of mGluR5 inhibitor NOE-101 in trigeminal neuralgia.

ImmunoGen and Eli Lilly and Company have entered into an agreement that gives Lilly exclusive rights to research, develop, and commercialize ADCs designed for targets selected by Lilly from ImmunoGen’s camptothecin technology.

In this episode of the Drug Solutions Podcast, Chris Spivey, editorial director, and Meg Rivers, senior editor, interview Sean Tucker, PhD, chief scientific officer of Vaxart, on developing oral recombinant vaccines.